



PRECEPTORSHIP PROGRAMME Lung Cancer Multidisciplinary management, standards of care and future perspectives

MANCHESTERUNITED KINGDOM

6-8 MARCH 2019

Co-Chairs Fiona Blackhall, UK Raffaele Califano, UK

esmo.org

ESMO-THE CHRISTIE PRECEPTORSHIP PROGRAMME **LUNG CANCER**

Multidisciplinary management, standards of care and future perspectives

Manchester, United Kingdom 6-8 March 2019

CO-CHAIRS:

Fiona Blackhall, United Kingdom Raffaele Califano, United Kingdom

SPFAKERS:

Mo Al Aloul, United Kingdom
Paul Baas, Netherlands
Haval Balata, United Kingdom
Neil Bayman, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
David Cobben, United Kingdom
Simon Ekman, Sweden
Martin Früh, Switzerland
Pilar Garrido López, Spain
Sven Hillinger, Switzerland
Keith M. Kerr, United Kingdom
Rohit Kochhar, United Kingdom
Jaroslaw Kuzdzal, Poland

Cecile Le Péchoux, France
Catherine McBain, United Kingdom
Luis Paz-Ares, Spain
David Planchard, France
Martin Reck, Germany
Suresh Senan, Netherlands
Hamid Sheikh, United Kingdom
Tora S. Solheim, Norway
Yvonne Summers, United Kingdom
Paul Taylor, United Kingdom
Fiona Thistlethwaite, UK
Paul E. Van Schil, Belgium
David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early stage Non-Small-Cell Lung Cancer and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

ACCREDITATION

The programme of this event has been accredited with 15 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from







Wednesday, 6 March 2019

08:15-09:15 60'	Registration	
09:15-10:55 100'	SESSION 1 Screening and diagnostics for lung cancer	Chairs: Raffaele Califano, UK Keith M. Kerr, UK
40'	Lung cancer screening: Pro and contra	Haval Balata, UK
30'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
30'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
10:55-11:15	Coffee break	
11:15-12:15 60'	SESSION 1 - cont. Screening and diagnostics for lung cancer	Chair: Raffaele Califano, UK
30'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
30'	Medical thoracoscopy in the management of thoracic malignancies	Mo Al Aloul, UK
12:15-13:15	Lunch	
13:15-15:35 120'	SESSION 2 Radical treatment of early stage NSCLC	Chairs: Sven Hillinger, CH Cecile Le Péchoux, FR
	, , , , , , , , , , , , , , , , , , , ,	Occine to recommendation in
30'	Surgery for early stage NSCLC	Sven Hillinger, CH
30'		
	Surgery for early stage NSCLC	Sven Hillinger, CH
30'	Surgery for early stage NSCLC Stereotactic ablative RT for early stage NSCLC	Sven Hillinger, CH
30' 14:15-14:35	Surgery for early stage NSCLC Stereotactic ablative RT for early stage NSCLC Coffee break	Sven Hillinger, CH Suresh Senan, NL
30' 14:15-14:35 30'	Surgery for early stage NSCLC Stereotactic ablative RT for early stage NSCLC Coffee break Adjuvant RT for completely resected early stage NSCLC	Sven Hillinger, CH Suresh Senan, NL Cecile Le Péchoux, FR
30' 14:15-14:35 30' 30' 15:35-16:05	Surgery for early stage NSCLC Stereotactic ablative RT for early stage NSCLC Coffee break Adjuvant RT for completely resected early stage NSCLC Adjuvant chemotherapy for resected early stage NSCLC SESSION 3	Sven Hillinger, CH Suresh Senan, NL Cecile Le Péchoux, FR Paul Taylor, UK

Thursday, 7 March 2019

09:05-10:05 60'	SESSION 3 - cont. Advanced NSCLC	Chairs: Luis Paz-Ares, ES Martin Reck, DE
30'	First-line Immune Checkpoint blockade for NSCLC	Luis Paz-Ares, ES
30'	Second-line treatment for advanced NSCLC	Martin Reck, DE
10:05-11:05 60'	SESSION 3 - cont. Advanced NSCLC	Chairs: Raffaele Califano, UK Yvonne Summers, UK

11:05-11:25	Coffee break	
11:25-12:25 60'	SESSION 3 - cont. Advanced NSCLC	Chairs: Raffaele Califano, UK Yvonne Summers, UK
30'	Maintenance treatment for advanced NSCLC	Yvonne Summers, UK
30'	Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
12:25-13:30	Lunch	
13:30-15:00 90'	SESSION 4 Palliative treatment of lung cancer and mesothelioma	Chairs: Paul Baas, NL Catherine McBain, UK
30'	Systemic treatment of mesothelioma	Paul Baas, NL
30'	Treatment of oligometastatic NSCLC	Jaroslaw Kuzdzal, PL
30'	Radical treatment of brain metastases: The importance of a neuro-oncology multidisciplinary approach	Catherine McBain, UK
15:00-15:20	Coffee break	
15:20-16:20 60'	SESSION 4 - cont. Palliative treatment of lung cancer and mesothelioma	Chairs: Raffaele Califano, UK Tora S. Solheim, NO
30'	Supportive and palliative care in lung cancer	Tora S. Solheim, NO
30'	Intraluminal RT	Hamid Sheikh, UK
16:20-16:30 10'	Close of day 2	Chair: Raffaele Califano, UK
19:00	Welcome drink	
19:30	Dinner	

Friday, 8 March 2019

09:10-10:40 90'	SESSION 5 Locally advanced NSCLC	Chairs: Paul E. Van Schil, BE David Woolf, UK
30'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
30'	Combined modality treatment for NSCLC with N2 disease	Clara Chan, UK
30'	Role of surgery for N2 disease	Paul E. Van Schil, BE
10:40-11:00	Coffee break	
11:00-12:00 60'	SESSION 5 - cont. Locally advanced NSCLC	Chairs: David Cobben, UK Paul E. Van Schil, BE
60'	Participants clinical case discussion (3x20')	Faculty

Each 20 min slot for clinical case discussion includes 10' case presentation and 10' Q&A / interactive panel discussion

12:00-13:00	Lunch				
-------------	-------	--	--	--	--

13:00-14:30 90'	SESSION 6 SCLC	Chairs: David Cobben, UK Pilar Garrido López, ES
30'	Treatment of limited stage SCLC	David Cobben, UK
30'	Targeted agents in SCLC	Pilar Garrido López, ES
30'	Treatment of extensive stage SCLC	Martin Früh, CH
14:30-14:50	Coffee break	
14:50-15:50 60'	SESSION 6 - cont. SCLC	Chairs: Raffaele Califano, UK David Cobben, UK
60'	SCLC Prophylactic cranial irradiation and role of thoracic RT for	David Cobben, UK

ORGANISATIONS AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4

6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org

The Christie School of Oncology
The Christie NHS Foundation Trust

Wilmslow Road Manchester M20 4BX United Kingdom

Email: education.events@christie.nhs.uk www.christie.nhs.uk/soo-events



